Skip to content
naulon
Not checkedNot checked for notices yet.

Line probe assay, a rapid and efficient test for the diagnosis of multidrug-resistant tuberculosis in Egypt

Aya M Azmy, Khaled Al-Amry, Salah El Deen Abdel Karim

Egyptian Journal of Chest Disease and Tuberculosis · 2020

doi:10.4103/ejcdt.ejcdt_111_19 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Background Earlier detection of tuberculosis (TB) and multidrug-resistant tuberculosis (MDR-TB) is crucial to preclude TB. We examined a genotypic drug sensitivity testing method for drug-resistant TB diagnosis using the line probe method as a rapid and technically simple method. The test used mutation-specific probes to determine isoniazid (INH) and rifampin resistance (RIF). Patients and methods The study was carried out on 82 Mycobacterium tuberculosis isolates that were identified phenotypically as MDR-TB isolates. The GenoBlot assay was assessed for fast detection of both rifampicin (RIF) and INH resistance against conventional phenotypic anti-TB drug sensitivity testing. The results were contrasted with the phenotypic drug susceptibility testing (DST) results of targeted samples; the turnaround time for both methods was evaluated. Results Compared with classical DST on solid media (Lowenstein Jensen), the line probe assay (LPA) technique had a relatively high concordance rate. The sensitivity to rifampicin was 94 and 91.5% for INH, and both showed 100% specificity. The consumed time for results by LPA was 24–48 h, while required 26 days for phenotypic culture on solid media and a supplemental 44 days for phenotypic DST. Conclusion LPA is a rapid, sensitive, easy to use, and efficient genotypic DST for MDR-TB detection.

Abstract licence: CC BY-NC-SA

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.